Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

China News

11/15/2024
BreakingCataractChinaDry EyeGlaucomaIOLLaserRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

11/15/2024
BreakingChinaDealsRetina
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million

Clearside Biomedical’s Asia-Pacific partner, Arctic Vision, announced Nov. 7 that it had licensed Chinese commercialization rights for ARVN001, marketed in the US as Xipere, to Santen Pharmaceutica...

11/8/2024
BreakingChinaGene TherapyRegulationRetina
US FDA Gives Green Light to Phase I Trial of HuidaGene’s CRISPR RNA-Editing Candidate for Wet AMD
US FDA Gives Green Light to Phase I Trial of HuidaGene’s CRISPR RNA-Editing Candidate for Wet AMD

HuidaGene Therapeutics announced Nov. 4 that the US FDA had cleared its investigational new drug (IND) application for a Phase I trial of HG202, a gene therapy candidate targeting wet age-related m...

10/15/2024
ChinaClinical TrialDealsDiagnosticDry EyeEuropeGene TherapyGlaucomaIndiaIndustryLaserNewsletterPerimetryRegulationRetinaSurgical
October 2024 Ophthalmic News Briefs
October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

9/20/2024
AllergyBreakingChinaDealsRegulation
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China

France’s Nicox announced Sept. 18 that partner Ocumension Therapeutics had received regulatory approval in China to commercialize Nicox’ Zerviate (cetirizine ophthalmic solution) 0.24% for ocular i...

9/6/2024
AmblyopiaBreakingChinaRegulation
NovaSight Gains Approval in China for CureSight System for Amblyopia
NovaSight Gains Approval in China for CureSight System for Amblyopia

Israel-based NovaSight reported Sept. 4 that its CureSight eye-tracking system for amblyopia in children had gained approval from Chinese regulators, expanding the device’s availability to the thre...

8/21/2024
ChinaDealsDry EyeNewsletterPharma
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake

China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...

8/16/2024
BreakingChinaDealsDry EyePharma
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake

China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...

7/26/2024
BreakingChinaLow VisionRetinaSurgical
Samsara Says First SING IMT for AMD Has Been Implanted in China
Samsara Says First SING IMT for AMD Has Been Implanted in China

Samsara Vision, of Far Hills, New Jersey, announced July 22 that the first SING IMT procedure for age-related macular degeneration (AMD) had been completed in China. The SING IMT, which stands for ...

7/23/2024
ChinaEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2024
Emerging Companies Pursuing Ophthalmic Indications, July 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

7/11/2024
BreakingChinaEmergingRetina
China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME
China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME

China’s DP Technology announced July 8 that it would advance DPT0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a potential oral treatment candidate for...

6/24/2024
ChinaIOLNewsletterRegulation
Volume-Based Procurement Could Upend China’s IOL Market
Volume-Based Procurement Could Upend China’s IOL Market

Alcon offered big discounts in China’s public sector centralized volume-based procurement (VBP) cycle for intraocular lenses (IOLs). The company’s low bids in seven of the eight bidding categories ...

5/24/2024
BreakingChinaRegulation
Chinese Regulators Accept NDA from Innovent for IBI311 in Thyroid Eye Disease
Chinese Regulators Accept NDA from Innovent for IBI311 in Thyroid Eye Disease

China’s Innovent Biologics announced May 20 that Chinese regulators had accepted the new drug application for IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody for thyroid e...

5/22/2024
CataractChinaCornealDiagnosticDry EyeGlaucomaIndiaMicroscopesNewsletterPharmaRegulationRetina
May 2024 Ophthalmic News Briefs
May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

5/10/2024
BreakingChinaDiagnosticRefractive
ArcScan Computer-Controlled Ophthalmic Ultrasound Gains Approval in China
ArcScan Computer-Controlled Ophthalmic Ultrasound Gains Approval in China

ArcScan announced May 1 that its Insight 100 computer-controlled ophthalmic ultrasound imaging device received National Medical Products Administration (NMPA) approval in China. ArcScan, of Denver,...

3/21/2024
ChinaIndiaMeetingMyopiaNewsletter
2024 APAO Congress Brainstorms How to Expand Access to Eye Care; Companies Showcase Tech Boom
2024 APAO Congress Brainstorms How to Expand Access  to Eye Care; Companies Showcase Tech Boom

Nearly 7,800 delegates attended the 2024 congress of the Asia-Pacific Academy of Ophthalmology in southern Bali from Feb. 22-25. The 253 sessions and 120 exhibits spread across four floors in two n...

2/23/2024
AllergyBreakingCataractChinaPharma
Regulators in Singapore Accept NDA from AffaMed for Dextenza
Regulators in Singapore Accept NDA from AffaMed for Dextenza

Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...

2/23/2024
BreakingChinaClinical Trial
Phase II/III Trial of Innovent’s TED Candidate Meets Primary Endpoint
Phase II/III Trial of Innovent’s TED Candidate Meets Primary Endpoint

China’s Innovent Biologics announced Feb. 19 that the primary endpoint had been achieved in the company’s Phase II/III trial of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF...

2/22/2024
ChinaDry EyeIndustryNewsletter
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets

Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...

2/16/2024
BreakingChinaIOLRefractiveRevenueSurgical
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya

Carl Zeiss Meditec reported Feb. 9 that ophthalmology revenue for the last three months of 2023, its first quarter of fiscal year 2023/2024, totaled €351.1 million ($378.5 million, converted Feb. 9...

11/21/2023
ChinaDealsDiagnosticDry EyeGene TherapyGenericsGlaucomaIndustryNewsletterPresbyopiaRegulationRetinaSurgical
November 2023 Ophthalmic News Briefs
November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

10/27/2023
BreakingChinaClinical TrialGene TherapyRetina
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD

China’s Skyline Therapeutics announced Oct. 19 that the National Medical Products Administration had cleared its investigational new drug application for a clinical trial of SKG0106, a one-time int...

10/24/2023
ChinaDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Emerging Companies Pursuing Ophthalmic Indications, October 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/13/2023
BreakingChinaDealsIOL
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market

China’s AffaMed Technologies announced Oct. 10 that it had entered into an agreement with SIFI, of Italy, to manufacture, develop, and commercialize SIFI’s Evolux enhanced monofocal intraocular len...

10/13/2023
BreakingChinaClinical TrialPharmaRetina
First Patient Dosed in Phase III Trial of Innovent’s Anti-VEGF, Anti-Complement Candidate for Wet AMD
First Patient Dosed in Phase III Trial of Innovent’s Anti-VEGF, Anti-Complement Candidate for Wet AMD

China’s Innovent Biologics announced Oct. 8 that the first patient had been dosed in a Phase III trial of efdamrofusp alfa (IBI302), a recombinant fully human anti-VEGF and anti-complement bispecif...

9/29/2023
BreakingChinaDealsDry EyeEurope
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate

London-based CS Pharmaceuticals reported July 28 that it had acquired AxeroVision, of Carlsbad, California, and its AXR-270 candidate for dry eye disease. The company did not report financial detai...

9/21/2023
ChinaClinical TrialCornealDealsDiagnosticDry EyeEuropeGene TherapyIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2023 Ophthalmic News Briefs
September 2023 Ophthalmic News Briefs

Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...

9/8/2023
BreakingChinaClinical TrialGene TherapyRegulationRetina
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate

Neurophth Therapeutics announced Sept. 6 that the Australian Therapeutic Goods Administration had cleared its gene therapy candidate NFS-05 for clinical trials targeting autosomal dominant optic at...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more